Notably, Figure 4 demonstrates significant upregulation of FGD5-AS1 in six various categories of cancers (P < 0.01), including pancreatic adenocarcinoma (PAAD), cholangiocarcinoma (CHOL), lower-grade glioma (LGG) of the brain, diffuse large B-cell lymphoma (DLBCL), glioblastoma multiforme (GBM), and clear cell renal carcinoma of the kidney (KIRC). Here, FGD5 is linked to cholangiocarcinoma.